Diagnostic value of β-D-glucan alone or combined with Candida score, colonization index and C-reactive protein for candidemia

Sumeyye Kazancioglu¹, Aliye Bastug², Bircan Kayaaslan³, Nevzat Mehmet Mutlu⁴, Esin Calci⁵, Turan Turhan⁶, Ipek Mumcuoglu⁷, Esragul Akinçı², Hurrem Bodur²

¹ Department of Infectious Diseases and Clinical Microbiology, Ankara City Hospital, Ankara, Turkey
² Department of Infectious Diseases and Clinical Microbiology, Health Science University Turkey, Ankara City Hospital, Ankara, Turkey
³ Department of Infectious Diseases and Clinical Microbiology, Yildirim Beyazit University, Ankara City Hospital, Ankara, Turkey
⁴ Department of Anesthesiology, Ankara City Hospital, Ankara, Turkey
⁵ Department of Clinical Biochemistry, Uşak Public Health laboratory, Uşak, Turkey
⁶ Department of Clinical Biochemistry, Ankara City Hospital, Ankara, Turkey
⁷ Department of Clinical Microbiology, Ankara City Hospital, Ankara, Turkey

Abstract

Introduction: Candidemia causes high mortality and is occurring at increasing rate in intensive care units (ICUs). (1,3)-β-D-glucan (BDG) testing is recommended in neutropenic patients. However, the usefulness of BDG in ICUs is unclear.

Methodology: This study was conducted to compare the diagnostic value of Candida score (CS), colonization index (CI), serum BDG detection, and routine laboratory parameters in ICU patients. Characteristics and laboratory data of 83 patients (15 patients with candidemia and 68 patients without candidemia) were evaluated.

Results: Median serum BDG was significantly higher in the candidemia group (129 pg/mL vs. 36 pg/mL, p < 0.001). BDG assay with standard cut-off value ≥ 80 pg/mL had 93.33% sensitivity and 64.18% specificity (Areas under the ROC curve (AUC): 0.788). This study concluded that the optimal cut-off value for BDG assay was 112 pg/mL with sensitivity of 86.67% and specificity of 82.09% (AUC: 0.844). C-reactive protein (CRP) with optimal cut-off value ≥ 85 mg/L and BDG ≥ 80 pg/mL had the highest AUC (0.862, 95% CI: 0.768 - 0.928) with sensitivity 93.33% and specificity 79.1%.

Conclusions: Predicting candidemia is essential in critically ill patients who are at high risk and have high mortality rates. The results of this study suggest that BDG testing is useful for predicting candidemia in ICU. However, BDG combined with CRP may be a stronger predictor for candidemia.

Key words: Candidemia; (1,3)-β-D-glucan; C-reactive protein; ICU.

J Infect Dev Ctries 2022; 16(2):362-368. doi:10.3855/jidc.15711

(Received 07 August 2021 – Accepted 13 January 2022)

Copyright © 2022 Kazancioglu et al. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Invasive fungal infections are common nosocomial infections [1]. Candidemia is a blood-stream infection observed at increasing rates in non-neutropenic patients admitted to intensive care units (ICUs) and causes high mortality [2,3]. Risk factors of candidemia such as total parenteral nutrition (TPN), central venous catheterization (CVC), immunosuppressive agents, and surgery are well described in ICUs [4-6]. However, diagnosis of candidemia is challenging because the standard methods (e.g. clinical signs and symptoms, host risk assessment, physical examination, radiography) are not specific [7]. Blood culture is the gold standard test for candidemia diagnosis. However, blood culture positivity rates are 40 - 60% for candidemia, and culture incubation for at least 3-4 days is required [8,9]. Therefore, clinical prediction rules or scoring systems for invasive candidiasis have been developed. Colonization index (CI) and Candida score (CS) ≥ 3 are used in clinical practice in ICUs [10,11].

Testing (1,3)-β-D-glucan (BDG), a polysaccharide in the fungal cell wall, becomes important in the diagnosis of candidemia. BDG testing appears to be useful for patients with hematological malignancies and BDG testing is recommended in neutropenic patients [12].

This study was conducted to compare the diagnostic value of CS, CI, serum BDG detection, and routine
laboratory parameters in a prospective cohort of ICU patients at risk for *Candida* bloodstream infection.

**Methodology**

**Study design and participants**

This study was approved by the ethics committee of Ankara Numune Training and Research Hospital (No: E-15-540). The study was conducted in a 26-bed adult ICU of a tertiary training and research hospital. All patients consecutively admitted to ICU for four months were eligible for enrollment in this study. Patients were enrolled if they stayed in the ICU for more than seven days, had not been diagnosed with and treated for invasive fungal infection (IFI) at baseline, and had neutrophil count ≥ of 500/mm³. Age, gender, Acute Physiology and Chronic Health Evaluation (APACHE), systemic inflammatory response syndrome (SIRS) score, primary diagnosis, presence of various known risk factors for candidiasis (for example, an indwelling CVC, broad-spectrum antibiotic therapy, immunosuppression or malignancy, mechanical ventilation, hemodialysis, hospitalization time in ICU longer than ten days, coexisting bacteremia, TPN, abdominal surgery, fever conditions, existing bacterial infections, laboratory values (C-reactive protein (CRP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), hemoglobin level, platelet and white blood cell (WBC) counts, glomerular filtration rate, blood culture results, and outcome were recorded. Variables potentially influencing BDG test results such as β-lactam antibiotics, renal replacement therapy, bloodstream infection, laboratory values (C-reactive protein (CRP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), hemoglobin level, platelet and white blood cell (WBC) counts, glomerular filtration rate, blood culture results, and outcome were recorded. For all patients, specimen from the *Candida* surveillance sites, such as the rectum, oropharynx, skin (axillary surface), urinary tract, and tracheal aspirate cultures were obtained on the day of admission to the ICU and once a week thereafter until discharge from the ICU or death. Corn Meal agar was used for *Candida* isolation and species definition. Specimen for cultures from other anatomical sites (such as a wound) were ordered as clinically indicated by the attending physician. BDG assay (from a peripheral venipuncture) and blood cultures (from a peripheral venipuncture and/or intravascular catheter) were obtained on the day of admission to the ICU and once a week thereafter until discharge from the ICU or death. Blood cultures were also obtained when the patient had fever and/or at the onset of sepsis. Blood cultures were processed using the automated BACTEC system (Becton Dickinson Diagnostic Instruments, Sparks, MD, USA).

Although blood and microbiological samples were taken prospectively, clinical follow-up and treatment status of the patients was not interfered with by the researchers. Patients receiving prophylactic or empirical antifungal agents were excluded from the study.

**Candida score and Colonization index**

CS and CI were calculated from the results of the patients’ surveillance cultures that were available once a week. CS with a cut-off value of 3 was as follows: TPN × 1, plus surgery × 1, plus multifocal *Candida* colonization × 1, plus severe sepsis × 2. The colonization index was calculated as the ratio of the number of culture-positive surveillance sites to the total number of sites cultured. The cut-off points were taken as ≥ 3 for CS and ≥ 0.5 for CI [10,13]. Maximum values recorded for CS and colonization index in each patient at or before candidemia were used in the analysis. In the absence of candidemia, the maximum of all observed values was used.

**BDG Assay**

Samples were collected in serum separation tubes and centrifuged within 30 minutes of collection. Samples were separated into aliquots and were frozen at -20°C until they were assayed. BDG measurements were performed in batches, and samples had no more than two freeze-thaw cycles. BDG concentrations were measured using a commercially available Fungitell test kit following manufacturer’s recommendation (Associates of Cape Cod Inc, East Falmouth, MA). Measurable ranges were 31, 25-500 pg/mL. BDG concentrations of < 60 pg/mL were interpreted as negative, ≥ 80 pg/mL as positive and 60-79 pg/mL as intermediate result. Hemolysis, lipemia, and apparent bilirubin interfered with the measurement and results. All samples were analyzed in triplicate and the mean value was used for further analysis.

**Statistical analysis**

Data were analyzed using IBM SPSS Statistics 20.0 (IBM Corporation, Armonk, NY, USA). Normally distributed continuous variables were reported as mean ± SD, and compared using Student’s *t*-test. Medians with ranges were used to describe non-normally distributed continuous variables, and compared using the Mann-Whitney U-test. Comparisons for categorical variables were executed using the Pearson Chi-square test or Fisher’s exact test. The receiver operation characteristic (ROC) curve analysis was used to determine the efficacy of BDG, CS, and CI for
discerning the patients with candidemia. Statistical significance was defined as \( p < 0.05 \).

**Results**

Of the 137 patients admitted to ICU during the study period, 83 met the inclusion criteria specified above, and were enrolled in the study. Characteristics of the 83 patients (15 in the candidemia group and 68 in the group without candidemia) are shown in Table 1. Mean age of the patients was 68.3 ± 17.0 years. 56.6% of the patients were male. Age and gender were not significantly different between candidemia and non-candidemia groups. Candidemia patients stayed longer in the ICU (43.5 ± 31.7 vs. 16.3 ± 8.6 days, \( p = 0.05 \)). There were no differences in comorbidities between the groups. All candidemia patients had CVC and broad-to-spectrum antibiotics. The overall mortality rate was 45.8%. There was no significant association between gender and mortality (\( p = 0.830 \), 44.4% (n=16) in female vs 46.8% (n = 22) in male). Twelve (80%) of the patients with candidemia died. Mortality rate was significantly higher in patients with candidemia (\( p = 0.003 \)).

Candidemia was detected in 15 (18%) of the patients. Non-albicans Candida species were more common (10 of 15 patients, Candida parapsilosis; \( n = 5 \), Candida krusei; \( n = 3 \), Candida glabrata; \( n = 1 \), Candida famata; \( n = 1 \)). Candidemia often occurred in the last days of hospitalization (29.2 ± 25.2 days). Six patients did not receive appropriate antifungal therapy (Table 1, 2).

As shown in Table 1, the percentages of patients with sepsis and Gram-positive bacteremia were significantly higher in patients with candidemia (\( p < 0.05 \)). Nine patients (60%) had sepsis in the candidemia group. In the non-candidemia group, the presence of sepsis was found in eighteen patients (26.5%) due to the coexistence of Gram-negative and Gram-positive bacteremia in two patients (in 20 bacteremia cases).

| Table 1. Clinical characteristics of patients with or without candidemia. |
|---------------------------------|-----------------|-----------------|-----------------|
|                                | Total (\( n = 83 \)) | Candidemia (\( n = 15 \)) | Non-candidemia (\( n = 68 \)) | \( p \)-value |
| Age, median years              | 68.3 ± 17.0       | 71.8 ± 14.8      | 67.6 ± 17.5      | 0.67         |
| Male (%)                       | 47 (56.6)         | 8 (53.3)         | 39 (57.3)        | 0.78         |
| APACHE score                   | 23.7 ± 7.9        | 25 ± 5.5         | 23.4 ± 8.4       | 0.48         |
| ICU stay, median               | 21.2 ± 18.6       | 43.5 ± 31.7      | 16.3 ± 8.6       | 0.05*        |
| **Underlying diseases (n, %)** |                 |                 |                 |             |
| Diabetes mellitus              | 20 (24.1)         | 6 (40)           | 20 (29.4)        | 0.540        |
| Hypertension                   | 45 (54.2)         | 10 (66.7)        | 35 (51.5)        | 0.290        |
| Immunosupression/malignancy    | 15 (18.1)         | 3 (20)           | 12 (17.6)        | 1.000        |
| COPD                           | 18 (21.7)         | 3 (20)           | 15 (22.1)        | 1.000        |
| Chronic renal failure          | 10 (12)           | 1 (6.7)          | 9 (13.2)         | 0.680        |
| Coronary arterial disease      | 32 (38.6)         | 7 (46.7)         | 25 (37.3)        | 0.480        |
| Cerebrovascular disease        | 29 (34.9)         | 4 (26.7)         | 25 (37.3)        | 0.460        |
| Surgery                        | 18 (21.7)         | 4 (26.7)         | 14 (20.6)        | 0.730        |
| **Risk factors (n, %)**        |                 |                 |                 |             |
| Broad to spectrum antibiotics  | 79 (94.0)         | 15 (100)         | 64 (94.1)        | 1.000        |
| Central venous catheter        | 68 (81.9)         | 15 (100)         | 53 (77.9)        | 0.060        |
| Total parenteral nutrition     | 55 (66.3)         | 12 (80)          | 43 (63.2)        | 0.210        |
| Abdominal surgery              | 4 (4.8)           | 1 (6.7)          | 3 (4.4)          | 0.560        |
| Mechanical ventilation         | 70 (84.3)         | 14 (93.3)        | 56 (82.4)        | 0.450        |
| Hemodialysis                   | 26 (31.3)         | 7 (46.7)         | 19 (27.9)        | 0.220        |
| ICU stay > 10 days             | 66 (79.5)         | 14 (93.3)        | 52 (76.5)        | 0.290        |
| **Clinical conditions**        |                 |                 |                 |             |
| Fever                          | 64 (77.1)         | 15 (100)         | 49 (72.1)        | 0.020*       |
| Sepsis                         | 27 (32.5)         | 9 (60)           | 18 (26.5)**  | 0.020*       |
| Pneumonia                      | 31 (37.3)         | 7 (46.7)         | 24 (35.3)        | 0.410        |
| Gram-positive bloodstream infection | 14 (16.9)    | 6 (40)           | 8 (11.8)         | 0.020*       |
| Gram-negative bloodstream infection | 15 (18.1)    | 3 (20)           | 12 (17.6)        | 1.000        |
| Positive BDG results           | 41 (49.4)         | 14 (93.3)        | 27 (39.7)        | 0.010*       |
| Colonization score value ≥ 3   | 25 (30.1)         | 10 (66.7)        | 15 (22.1)        | 0.001*       |
| Colonization index ≥ 0.5       | 11 (13.3)         | 6 (40)           | 5 (7.4)          | 0.025*       |
| ICU mortality                  | 38 (45.8)         | 12 (80)          | 26 (38.2)        | 0.003*       |

Data are mean ± SD or n (%). \( p \)-values comparing candidemia patients and non-candidemia patients. APACHE: Acute Physiology and Chronic Health Evaluation; ICU: Intensive care unit; COPD: Chronic obstructive pulmonary disease; BDG: (1,3)-β-D-glucan. * Statistical significance was defined as \( p < 0.05 \). ** The coexistence of Gram-negative and positive bacteremia in two patients.
Table 2. Characteristics of fifteen patients with candidemia.

| Patient No | Underlying Conditions | Age | Admission Diagnosis | CI  | CS  | BDG level | Treatment | Treatment time | Candida species | Hospital stay | The day of candidemia | Outcome |
|------------|-----------------------|-----|---------------------|-----|-----|-----------|-----------|---------------|----------------|--------------|----------------------|---------|
| 70         | Diabetes, hypertension, orthopedic surgery Malignancy, abdominal surgery | 89  | Wound infection | 0.4 | 4  | 37 | fluconazole | 0 | | C. parapsilosis | 10 | 10 | dead |
| 59         | Malignancy | 68  | Mediastinitis, pneumonia | 0.4 | 4  | 523 | - | 0 | C. parapsilosis | 44 | 41 | dead |
| 132        | Malignancy | 50  | Pneumonia | 0.4 | 4  | 417 | - | 0 | C. krusei | 18 | 13 | dead |
| 49         | Diabetes, hypertension, hypotension | 76  | Cerebrovascular event | 0.2 | 3  | 523 | - | 0 | C. krusei | 102 | 98 | dead |
| 48         | Hypertension | 73  | Encephalitis | 0.2 | 1  | 115 | anidulafungine | 4 | | C. albicans | 24 | 16 | alive |
| 41         | Hypertension, orthopedic surgery | 89  | Respiratory failure | 0.8 | 4  | 165 | - | 0 | C. parapsilosis | 21 | 16 | dead |
| 33         | Coronary artery disease, Diabetes, hypertension, coronary artery disease | 83  | Respiratory failure | 0.2 | 1  | 82 | fluconazole | 2 | | C. krusei | 14 | 8 | dead |
| 32         | Diabetes, hypertension, coronary artery disease | 84  | Respiratory failure | 0.6 | 3  | 523 | fluconazole | 1 | | C. albicans | 16 | 11 | dead |
| 19         | Diabetes, hypertension, Dementia, hypertension, trauma | 49  | Acute coronary syndrome | 0.2 | 1  | 523 | fluconazole | 7 | | C. glabrata | 58 | 6 | alive |
| 9          | Diabetes, hypertension, dementia | 81  | Subarachnoid hemorrhage | 0.8 | 4  | 523 | - | 0 | C. famata | 27 | 24 | dead |
| 6          | Diabetes | 76  | Pneumonia | 0.8 | 3  | 236 | fluconazole | 2 | | C. albicans | 45 | 28 | dead |
| 104        | Diabetes, hypertension, Dementia | 63  | Listeria meningitis | 0.2 | 0  | 369 | fluconazole | 4 | | C. parapsilosis | 50 | 40 | alive |
| 99         | Diabetes, hypertension, Dementia, hypertension, trauma | 69  | Pneumonia | 0.4 | 3  | 461 | anidulafungine | 1 | | C. albicans | 106 | 20 | dead |
| 21         | Dementia, hypertension, trauma | 84  | Respiratory failure | 0.8 | 4  | 523 | - | 0 | C. albicans | 62 | 59 | dead |
| 66         | Chronic renal failure, quadriplegic | 43  | Pneumonia | 0.4 | 2  | 144 | caspofungine | 4 | | C. parapsilosis | 73 | 51 | dead |

CI: Colonization index; CS: Candida score; BDG: (1,3)-β-D-glucan.

Table 3. Laboratory parameters of patients with and without candidemia.

| Parameter               | Total (n = 83) | Candidemia (n = 15) | No-candidemia (n = 68) | p-value |
|------------------------|---------------|---------------------|------------------------|---------|
| Leucocytes             | 11200 (3200-37900) | 15300 (3200-31000) | 11050 (4400-37900) | 0.290   |
| Neutrophils            | 8900 (100-33200) | 11800 (300-28700) | 8850 (100-32000) | 0.520   |
| Lymphocytes            | 1100 (200-7200) | 1500 (200-7200) | 1100 (200-3500) | 0.210   |
| Platelets              | 195000 (8800-588000) | 173000 (24000-461000) | 205000 (8800-588000) | 0.500   |
| Hemoglobin             | 9.9 (6.7-13.4) | 9.5 (7.3-13.0) | 10.0 (6.7-13.4) | 0.540   |
| ALT                    | 26 (3-712) | 19 (4-712) | 26.5 (3-325) | 0.990   |
| AST                    | 32 (1-1118) | 60 (17-365) | 29.5 (1-1118) | 0.820   |
| GFR                    | 41.3 (7-60) | 32 (20-60) | 49.5 (7-60) | 0.680   |
| CRP                    | 122.4 (2-356) | 124 (86-317) | 90 (2-356) | 0.020*  |
| NLR                    | 8.2 (0.08-133) | 7.6 (0.08-94) | 8.8 (0.11-133) | 0.670   |
| BDG level              | 68 (0-523) | 129 (8-523) | 36 (0-523) | < 0.001* |

ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, GFR: Glomerular filtration rate, CRP: C-reactive protein, NLR: Neutrophil-to-lymphocytes ratio, BDG: (1,3)-β-D-glucan. * Statistical significance was defined as p < 0.05.
Fever was also significantly higher in the group with candidemia ($p = 0.020$). There was no difference in underlying diseases between the two groups. There were only two patients in the non-candidemia group who were treated with corticosteroids. Therefore, the relationship between corticosteroids and candidemia could not be analyzed.

Routine laboratory parameters are shown in Table 3. Significantly higher CRP, leucocytes, neutrophils, and lower platelets were found in the candidemia group.

Several surveillance specimens from the 83 patients were screened for the presence of Candida species. Candida species colonized in at least one anatomical site in all patients in the candidemia group with colonization index $\geq 0.5$, and was found in $9\%$ ($6/68$) of non-candidemia patients and $33.3\%$ ($5/15$) of patients with candidemia ($p = 0.025$). CS $\geq 3$ was found in $22.1\%$ ($15/68$) of non-candidemia patients and in $66.7\%$ ($10/15$) of patients with candidemia ($p = 0.001$).

BDG positivity was higher in the candidemia group than in the non-candidemia group. BDG positivity was found in all but one of the candidemia patients. Among the patients who had no candidemia, 27 of 68 patients tested were BDG-positive. But 23 of these 27 patients had $\geq 2$ false-positive factors. The median serum BDG was significantly higher in the candidemia group ($129$ pg/mL vs. $36$ pg/mL, $p < 0.001$) (Figure 1).

Diagnostic test indices for candidemia are presented in Table 4. BDG assay with a standard cut-off value $\geq 80$ pg/mL had $93.33\%$ sensitivity and $64.18\%$ specificity (Area under the curve (AUC): $0.788$). This study demonstrated that the optimal cut-off value for BDG assay was $112$ pg/mL with sensitivity of $86.67\%$ and specificity of $82.09\%$ (AUC: $0.844$).

### Table 4. ROC analysis for the diagnosis of candidemia.

| Sensitivity   | Specificity | $+ \text{LR}$ | $- \text{LR}$ | $+ \text{PV}$ | $- \text{PV}$ | AUC | 95% CI     | $p$-value |
|--------------|-------------|---------------|---------------|---------------|---------------|-----|-----------|-----------|
| BDG $\geq 80$ pg/mL | 93.33       | 64.18         | 2.61          | 0.1           | 36.8          | 97.7| 0.788     | 0.683-0.870| $< 0.0001^*$|
| BDG $\geq 112$ pg/mL | 86.67       | 82.09         | 4.84          | 0.16          | 52            | 96.5| 0.844     | 0.747-0.915| $< 0.0001^*$|
| CI $\geq 0.5$ | 33.33       | 91.04         | 3.72          | 0.73          | 45.5          | 85.9| 0.622     | 0.508-0.727| 0.062      |
| CS $\geq 3$  | 66.67       | 77.94         | 3.02          | 0.43          | 40            | 91.4| 0.723     | 0.614-0.816| $0.001^*$  |
| CRP $\geq 85$ g/dL | 100         | 48.53         | 1.94          | 0             | 30            | 100 | 0.743     | 0.635-0.832| $< 0.0001^*$|
| Sepsis       | 60          | 66.04         | 1.77          | 0.61          | 33.3          | 85.4| 0.630     | 0.504-0.744| 0.076      |
| CRP $\geq 85$ g/dL + BDG $\geq 80$ pg/mL | 93.33       | 79.1          | 4.47          | 0.084         | 50            | 98.1| 0.862     | 0.768-0.928| $< 0.0001^*$|
| CRP $\geq 85$ g/dL + BDG $\geq 112$ pg/mL | 86.67       | 82.09         | 4.84          | 0.16          | 52            | 96.5| 0.844     | 0.747-0.915| $< 0.0001^*$|
| CI $\geq 0.5 + \geq 80$ pg/mL | 33.33       | 92.54         | 4.47          | 0.72          | 50            | 86.1| 0.629     | 0.516-0.733| 0.047*     |
| CI $\geq 0.5 + \geq 112$ pg/mL | 33.33       | 94.03         | 5.58          | 0.71          | 55.6          | 86.3| 0.637     | 0.523-0.740| 0.034*     |
| CS $\geq 3 +$ BDG $\geq 80$ pg/mL | 53.33       | 91.04         | 5.96          | 0.51          | 57.1          | 89.7| 0.722     | 0.612-0.815| $0.001^*$  |
| CS $\geq 3 +$ BDG $\geq 112$ pg/mL | 60          | 88.06         | 5.02          | 0.45          | 52.9          | 80.8| 0.740     | 0.632-0.831| $0.000^*$  |
| Sepsis + BDG $\geq 80$ pg/mL | 53.33       | 82.69         | 3.08          | 0.56          | 47.1          | 86  | 0.680     | 0.555-0.789| $0.012^*$  |
| Sepsis + BDG $\geq 112$ pg/mL | 46.67       | 84.62         | 3.03          | 0.63          | 46.7          | 84.6| 0.656     | 0.530-0.768| 0.028*     |

BDG: (1,3)-β-D-glucan; CI: Colonization index; CS: Candida score; CRP: C-reactive protein. * Statistical significance was defined as $p < 0.05$. 

---

**Figure 1.** (1,3)-β-D-glucan levels in patients with candidemia and without candidemia.

**Figure 2.** ROC analysis of (1,3)-β-D-glucan alone, (1,3)-β-D-glucan + C-reactive protein, and (1,3)-β-D-glucan + Candida score $\geq 3$ for the diagnosis of candidemia.
CRP with optimal cut-off value $\geq 85$ mg/L (based on this study) + BDG $\geq 80$ pg/mL had the highest AUC (0.862, 95% CI: 0.768 - 0.928) with sensitivity 93.33% and specificity 79.1%. CS $\geq 3$ was found to be associated with a diagnosis of candidemia whereas CI $\geq 0.5$ was not significantly associated. While sepsis alone was not a significant association in the diagnosis of candidemia, sepsis and BDG positivity were significantly associated with the diagnosis. The specificity increased when the BDG assay was evaluated with CI and CS instead of BDG assay on its own. The AUCs for BDG, CS, CI, and CRP were presented in Table 4 and Figure 2.

**Discussion**

Using CI, CS and BDG levels of patients in ICU were evaluated in this study. The patients included 15 with candidemia and 68 with no candidemia. In this study, the optimal cut-off value for BG level $\geq 112$ pg/mL was found to have sensitivity of 86.67% and specificity of 82.09% for the diagnosis of candidemia. CRP $\geq 85$ mg/L + BDG $\geq 80$ pg/mL had the highest AUC with high sensitivity and specificity. Additionally, it was observed that specificity for candidemia increased when the BDG assay was evaluated along with CI or CS.

According to a meta-analysis, sensitivity 81.3% (95% CI; 75.3% to 86.0%) and specificity 64.1% (95% CI; 55.6% to 71.8%) were estimated for BDG with standard cut-off value $\geq 80$ for candidemia [7]. Similarly, in this study BDG, with standard cut-off value $\geq 80$ pg/mL, sensitivity of 93.33% and 64.18% specificity. Higher negative predictive value (NPV) of BDG (97.7%) was found in this study, similar to previous reports in the literature; therefore BDG testing can also be useful for excluding candidemia [8]. However, CRP (optimal cut-off value 85 mg/L) + BG $\geq 80$ pg/mL had the highest AUC with sensitivity of 93.33% and specificity of 79.1%. The major uncertainty for BDG testing, particularly in high-risk populations in ICUs is poor specificity and positive predictive value (PPV). Similarly, in this study, BDG testing alone (with a cut-off of 80 pg/mL) had low specificity 64.18% and low PPV 36.8%. Therefore, when evaluated together with the increased optimal cut-off value (112 pg/mL) and CRP; specificity and PPV were found to be more diagnostic. Previously, Guo et al. reported that BDG combined with hscRP increased diagnostic value for candidemia [14]. CRP is a traditional inflammatory marker that can be useful for the diagnosis of candidemia. Miglietta et al. found CRP (cut-off value: 76.2 mg/L) had sensitivity of 77.2% and specificity of 63.6% for distinguishing candidemia from bacterial sepsis [15]. Therefore it was concluded that assessment of CRP and BDG together may be more useful to predict candidemia.

*Candida* colonization is a predictor of candidemia in ICUs. CI $\geq 0.5$ was more common in the candidemia group in this study. *Candida* colonization in combination with other risk factors such as TPN, surgery, and sepsis in ICU patients is more predictive for candidemia. Leon et al. showed that the AUC for CS $\geq 3$ was 0.774 (95% CI 0.715 – 0.832) with sensitivity 77.6%, specificity 66.2%) compared with 0.633 (95% CI 0.557 – 0.709) for CI [10]. In this study, the AUC for CS $\geq 3$ was 0.723 (95% CI 0.614 – 0.816) with sensitivity 77.94%, specificity 66.67%) compared with 0.622 (95% CI 0.508 – 0.727) for CI. It was suggested that BDG testing can be combined with other markers of candidemia (eg Candida score, *Candida albicans* germ tub antibody (CAGTA)) in ICUs [16]. The concerns over low positive predictive value (PPV) restrict use of BDG for the diagnosis of fungal infection in ICUs. A review article suggested that a combination of CS (two times a week) and non-culture microbiological tools for predicting candidemia in ICUs [17]. In this study, CS combined with BDG were found to be associated with improved specificity and PPV.

**Conclusions**

ICU patients represent a critical population to predict the diagnosis of candidemia due to high mortality rates. Blood culture is the gold standard test for candidemia diagnosis but the identification of a *Candida* species takes a long time. Our results suggest that BDG testing is useful for predicting candidemia. However, BDG combined with CRP (with an optimal cut-off value $\geq 85$ mg/L) could be more predictive with higher sensitivity and specificity.

**Acknowledgements**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. This study was presented as a poster at the VII. EKMUD International Congress in May 2018 and awarded the third poster prize.

**Authors’ Contributions**

SK and BK contributed to the conception, design, and data collection. SK contributed to the statistical analysis, literature research, drafting and revision of the manuscript. AB helped in drafting and revising of the manuscript. NMM participated in data collection from patients and analysis. AC, TT, and IM
References

1. Pfaffer MA, Diekema DJ (2010) Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 36: 1-53.
2. Bouza E, Munoz P (2008) Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents 32: 87-91.
3. Lortholary O, Renaudat C, Sibton K, Madec Y, Denoeud-Ndam L, Wolff M, Fontanet A, Bretagne S, Dromer F (2014) Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002–2010). Intensive Care Med 40: 1303-1312.
4. Poissy J, Damonti L, Bignon A, Khanna N, Von Kietzell M, Boggian K, Neofytos D, Vuotto F, Coiteux V, Artru F (2020) Risk factors for candidemia: a prospective matched case-control study. Crit Care 24: 1-11.
5. Keighley CL, Pope A, Marriott DJ, Chapman B, Bak N, Daveson K, Hajkowicz K, Halliday C, Kennedy K, Kidd S (2021) Risk factors for candidaemia: A prospective multicentre case-control study. Mycoses 64: 257-263.
6. Ostrosky-Zeichner L, Sable C, Sobel J, Alexander BD, Donowitz G, Kan V, Kauffman CA, Kett D, Larsen RA, Morrison V (2007) Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 26: 271-276.
7. White SK, Schmidt RL, Walker BS, Hanson KE (2020) (1→3)-β-D-glucan testing for the detection of invasive fungal infections in immunocompromised or critically ill people. Cochrane Database Syst Rev 7: CD009833.
8. Clancy CJ, Nguyen MH (2013) Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 56: 1284-1292.
9. Bassetti M, Azoulay E, Kulberg B-J, Ruhnke M, Shoham S, Vazquez J, Giacobbe DR, Calandra T (2021) EORTC/MSGERC definitions of invasive fungal diseases: summary of activities of the Intensive Care Unit Working Group. Clin Infect Dis 72: 121-127.
10. León C, Ruiz-Santana S, Saavedra P, Galván B, Blanco A, Castro C, Balasini C, Utande-Vázquez A, de Molina FJG, Blasco-Navalproto MA (2009) Usefulness of the “Candida score” for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 37: 1624-1633.
11. Posteraro B, De Pascale G, Tumbarello M, Torelli R, Pennisi Mariano A, Bello G, Maviglia R, Fadda G, Sanguinetti M, Antonelli M (2011) Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1→3)-β-D-glucan assay, Candida score, and colonization index. Critic Care 15: 1-10.
12. Theel ES, Doern CD (2013) Point-counterpoint: β-d-glucan testing is important for diagnosis of invasive fungal infections. J Clin Microbiol 51: 3478-3483.
13. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R (1994) Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 220: 751.
14. Guo J, Wu Y, Lai W, Lu W, Mu X (2019) The diagnostic value of (1, 3)-β-D-glucan alone or combined with traditional inflammatory markers in neonatal invasive candidiasis. BMC Infect Dis 19: 1-8.
15. Miglietta F, Faneschi ML, Lobreglio G, Palumbo C, Rizzo A, Cucurachi M, Portaccio G, Guerra F, Pizzolante M (2015) Procalcitonin, C-reactive protein and serum lactate dehydrogenase in the diagnosis of bacterial sepsis, SIRS and systemic candidiasis. Infez Med 23: 230-237.
16. Lamoth F, Faneschi ML, Lobreglio G, Palumbo C, Rizzo A, Cucurachi M, Portaccio G, Guerra F, Pizzolante M (2015) Procalcitonin, C-reactive protein and serum lactate dehydrogenase in the diagnosis of bacterial sepsis, SIRS and systemic candidiasis. Infez Med 23: 230-237.
17. Peman J, Zaragoza R (2010) Current diagnostic approaches to invasive candidiasis in critical care settings. Mycoses 53: 424-433.

Corresponding author
Sumeyye Kazancioglu, MD.
Department of Infectious Diseases and Clinical Microbiology, Sağlık Bakanlığı Ankara City Hospital, Üniversiteler Mahallesi 1604. Cadde No: 9 Çankaya/ ANKARA Postal Code: 06800
Phone: +90 505 375 03 36
Fax: +90 312 552 60 00
E-mail: sumeyye_yildiz@hotmail.com

Conflict of interests: No conflict of interests is declared.